Acute Myeloid Leukemia
We recommend
New scoring system for predicting long-term survival of AML patients over 70 years and suitable for intensive chemotherapy
Based on the analysis of data from 3 large European registries (DATAML, SAL, and PETHEMA), a prognostic score for 5-year survival was created and validated for patients with acute myeloid leukemia (AML) who were given intensive chemotherapy. The ESS70+ score, determined based on parameters known at the time of diagnosis, is easily usable in routine practice for estimating overall survival of older AML patients and facilitates decisions about intensive chemotherapy.
Maintenance Therapy of a Female Patient with AML After Intense Chemotherapy – Case Study
The following case study presents the case of a female patient with acute myeloid leukemia (AML)…
Impact of Azacitidine Maintenance Therapy on Survival of Patients with AML in Remission Depending on Initial Chemotherapy
The QUAZAR AML-001 study showed that oral azacitidine maintenance therapy significantly prolongs…
Articles on this topic
Journal articles Characteristics and results of treatment of younger patients less than 60 years old with AML: analysis of real data from the Czech DATOOL-AML database
Cílem této práce je retrospektivní analýza reálných klinických dat nemocných s akutní myeloidní...
1
2
Subscribe
Most read on this topic
Journal on this topic
Related topic
Most read on this topic
- Actual role of allogeneic haematopoietic transplantation in the treatment of acute myeloid leukaemia
- Novel molecules used in the targeted treatment of acute myeloid leukaemia – adverse reactions, treatment complications and signifi cant drug interactions
- Characteristics and results of treatment of younger patients less than 60 years old with AML: analysis of real data from the Czech DATOOL-AML database
- Effect of Azacitidine in the Treatment of Acute Myeloid Leukemia on Long-Term Patient Survival
- Current Position of Venetoclax in the Treatment of AML − Hope for a Better Prognosis?
- Oral Azacitidine Prolongs Survival of AML Patients Regardless of Measurable Residual Disease
Journal on this topic
Related topic